Equities researchers at HC Wainwright boosted their Q1 2025 earnings estimates for shares of ADC Therapeutics in a note ...

Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of HilleVax in a note issued to investors on Monday, March 31st. HC Wainwright analyst M. Caufield anticipates that the ...

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy ...

H.C. Wainwright analyst Douglas Tsao views the agreement of joint stipulation between Arcutis Biotherapeutics (ARQT) and Padagis to the ongoing ...

H.C. Wainwright initiated coverage of Kairos Pharma (KAPA) with a Buy rating and $12 price target The company’s oncology pipeline “could ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Knightscope, Inc. (NASDAQ: KSCP), a leader in developing autonomous security robots and artificial intelligence technologies, closed on the previously announced sale of an aggregate of 625,000 shares ...

Virax Biolabs' T-cell testing platform targets post-viral syndromes like Long COVID. HC Wainwright sees a major market opportunity, setting a $3 price target.

A replay of the presentation will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conference, please reach out to your respective H.C.